{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:04:01Z","timestamp":1789409041495,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00508-021-01967-z","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T23:02:12Z","timestamp":1636066932000},"page":"110-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hematocrit to hemoglobin ratio as a\u00a0prognostic marker in polycythemia vera"],"prefix":"10.1007","volume":"134","author":[{"given":"Ivan","family":"Kre\u010dak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Lucijani\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Zekanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrvoje","family":"Holik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Mori\u0107 Peri\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijana","family":"\u0160upe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo\u017eena","family":"Coha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velka","family":"Gveri\u0107-Kre\u010dak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"issue":"24","key":"1967_CR1","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.1182\/bloodadvances.2020003323","volume":"4","author":"HJCM Wouters","year":"2020","unstructured":"Wouters\u00a0HJCM, Mulder\u00a0R, van Zeventer\u00a0IA, Schuringa\u00a0JJ, van der Klauw\u00a0MM, van der Harst\u00a0P, et\u00a0al. Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis. Blood Adv. 2020;4(24):6353\u201363.","journal-title":"Blood Adv"},{"issue":"4","key":"1967_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41408-021-00463-x","volume":"11","author":"E Nguyen","year":"2021","unstructured":"Nguyen\u00a0E, Harnois\u00a0M, Busque\u00a0L, Sirhan\u00a0S, Assouline\u00a0S, Chamaki\u00a0I, et\u00a0al. Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera. Blood Cancer\u00a0J. 2021;11(4):75.","journal-title":"Blood Cancer J"},{"issue":"2","key":"1967_CR3","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1111\/ijlh.13373","volume":"43","author":"H Holik","year":"2021","unstructured":"Holik\u00a0H, Kre\u010dak\u00a0I, Gveri\u0107-Kre\u010dak\u00a0V, Vu\u010dini\u0107 Ljubi\u010di\u0107\u00a0I, Coha\u00a0B. Higher red blood cell distribution width might differentiate primary from secondary polycythemia: a pilot study. Int J Lab Hematol. 2021;43(2):e68\u2013e71.","journal-title":"Int J Lab Hematol"},{"issue":"5","key":"1967_CR4","first-page":"395","volume":"6","author":"VR Bhatt","year":"2014","unstructured":"Bhatt\u00a0VR. Secondary polycythemia and the risk of venous thromboembolism. J\u00a0Clin Med Res. 2014;6(5):395\u20137.","journal-title":"J Clin Med Res"},{"issue":"1","key":"1967_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ajh.23585","volume":"89","author":"T Barbui","year":"2014","unstructured":"Barbui\u00a0T, Thiele\u00a0J, Gisslinger\u00a0H, Finazzi\u00a0G, Carobbio\u00a0A, Rumi\u00a0E, et\u00a0al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2014;89(1):52\u20134.","journal-title":"Am J Hematol"},{"issue":"20","key":"1967_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber\u00a0DA, Orazi\u00a0A, Hasserjian\u00a0R, Thiele\u00a0J, Borowitz\u00a0MJ, Le Beau\u00a0MM, et\u00a0al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"4","key":"1967_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/ajcp\/aqw131","volume":"146","author":"L Busque","year":"2016","unstructured":"Busque\u00a0L, Porwit\u00a0A, Day\u00a0R, Olney\u00a0HJ, Leber\u00a0B, \u00c9thier\u00a0V, et\u00a0al. Laboratory investigation of myeloproliferative neoplasms (MPNs): recommendations of the Canadian MPN group. Am J Clin Pathol. 2016;146(4):408\u201322.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"1967_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bjh.15648","volume":"184","author":"MF McMullin","year":"2019","unstructured":"McMullin\u00a0MF, Harrison\u00a0CN, Ali\u00a0S, Cargo\u00a0C, Chen\u00a0F, Ewing\u00a0J, et\u00a0al. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology guideline. Br J Haematol. 2019;184(2):176\u201391.","journal-title":"Br J Haematol"},{"issue":"1","key":"1967_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli\u00a0R, Finazzi\u00a0G, Specchia\u00a0G, Cacciola\u00a0R, Cavazzina\u00a0R, Cilloni\u00a0D, et\u00a0al. Cardiovascular events and intensity of treatment in polycythemia vera. N\u00a0Engl J Med. 2013;368(1):22\u201333.","journal-title":"N Engl J Med"},{"issue":"2","key":"1967_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi\u00a0R, Marchioli\u00a0R, Kutti\u00a0J, Gisslinger\u00a0H, Tognoni\u00a0G, Patrono\u00a0C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N\u00a0Engl J Med. 2004;350(2):114\u201324.","journal-title":"N Engl J Med"},{"issue":"6","key":"1967_CR11","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R Landolfi","year":"2007","unstructured":"Landolfi\u00a0R, Di Gennaro\u00a0L, Barbui\u00a0T, De Stefano\u00a0V, Finazzi\u00a0G, Marfisi\u00a0R, et\u00a0al. Leukocytosis as a\u00a0major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109(6):2446\u201352.","journal-title":"Blood"},{"issue":"11","key":"1967_CR12","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","volume":"3","author":"A Carobbio","year":"2019","unstructured":"Carobbio\u00a0A, Ferrari\u00a0A, Masciulli\u00a0A, Ghirardi\u00a0A, Barosi\u00a0G, Barbui\u00a0T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a\u00a0systematic review and meta-analysis. Blood Adv. 2019;3(11):1729\u201337.","journal-title":"Blood Adv"},{"issue":"19","key":"1967_CR13","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1182\/blood.2019003347","volume":"135","author":"L Ronner","year":"2020","unstructured":"Ronner\u00a0L, Podoltsev\u00a0N, Gotlib\u00a0J, Heaney\u00a0ML, Kuykendall\u00a0AT, O\u2019Connell\u00a0C, et\u00a0al. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020;135(19):1696\u2013703.","journal-title":"Blood"},{"key":"1967_CR14","first-page":"139","volume":"43","author":"HH Hayuanta","year":"2016","unstructured":"Hayuanta\u00a0HH. Can hemoglobin-hematocrit relationship be used to assess hydration status? Cermin Dunia Kedokteran. 2016;43:139\u201342.","journal-title":"Cermin Dunia Kedokteran"},{"issue":"8","key":"1967_CR15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/j.1365-3156.2006.01679.x","volume":"11","author":"L Quint\u00f3","year":"2006","unstructured":"Quint\u00f3\u00a0L, Aponte\u00a0JJ, Men\u00e9ndez\u00a0C, Sacarlal\u00a0J, Aide\u00a0P, Espasa\u00a0M, et\u00a0al. Relationship between haemoglobin and haematocrit in the definition of anaemia. Trop Med Int Health. 2006;11(8):1295\u2013302.","journal-title":"Trop Med Int Health"},{"issue":"4","key":"1967_CR16","first-page":"707","volume":"44","author":"S Insiripong","year":"2013","unstructured":"Insiripong\u00a0S, Supattarobol\u00a0T, Jetsrisuparb\u00a0A. Comparison of hematocrit\/hemoglobin ratios in subjects with alpha-thalassemia, with subjects having chronic kidney disease and normal subjects. Southeast Asian J Trop Med Public Health. 2013;44(4):707\u201311.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"1967_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.leukres.2017.01.032","volume":"56","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek\u00a0S, Harrison\u00a0CN, Kiladjian\u00a0JJ, Miller\u00a0C, Naim\u00a0AB, Paranagama\u00a0DC, et\u00a0al. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Leuk Res. 2017;56:52\u20139.","journal-title":"Leuk Res"},{"issue":"10","key":"1967_CR18","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","volume":"32","author":"YZ Ginzburg","year":"2018","unstructured":"Ginzburg\u00a0YZ, Feola\u00a0M, Zimran\u00a0E, Varkonyi\u00a0J, Ganz\u00a0T, Hoffman\u00a0R. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018;32(10):2105\u201316.","journal-title":"Leukemia"},{"issue":"9464","key":"1967_CR19","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter\u00a0EJ, Scott\u00a0LM, Campbell\u00a0PJ, East\u00a0C, Fourouclas\u00a0N, Swanton\u00a0S, et\u00a0al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054\u201361.","journal-title":"Lancet"},{"key":"1967_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2165-7831.1000207","volume":"8","author":"\u00c1 Kellner","year":"2018","unstructured":"Kellner \u00c1, Kellner\u00a0V, Rajnics\u00a0P, Kar\u00e1di \u00c9, Ill\u00e9s \u00c1, Demeter\u00a0J, et\u00a0al. Low mean cell haemoglobin is a\u00a0valuable parameter of thrombotic risk stratification in patients with polycythemia vera. J\u00a0Blood Lymph. 2018;8:1.","journal-title":"J Blood Lymph"},{"issue":"13","key":"1967_CR21","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","volume":"100","author":"JL Spivak","year":"2002","unstructured":"Spivak\u00a0JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13):4272\u201390.","journal-title":"Blood"},{"issue":"1","key":"1967_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/cncr.21105","volume":"104","author":"S Sirhan","year":"2005","unstructured":"Sirhan\u00a0S, Fairbanks\u00a0VF, Tefferi\u00a0A. Red cell mass and plasma volume measurements in polycythemia: evaluation of performance and practical utility. Cancer. 2005;104(1):213\u20135.","journal-title":"Cancer"},{"issue":"4","key":"1967_CR23","doi-asserted-by":"publisher","first-page":"8281","DOI":"10.4081\/hr.2019.8281","volume":"11","author":"V Accurso","year":"2019","unstructured":"Accurso\u00a0V, Santoro\u00a0M, Raso\u00a0S, Contrino\u00a0AD, Casimiro\u00a0P, Piazza\u00a0FD, et\u00a0al. Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: a single center study. Hematol Rep. 2019;11(4):8281.","journal-title":"Hematol Rep"},{"issue":"3","key":"1967_CR24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.thromres.2013.12.013","volume":"133","author":"B Z\u00f6ller","year":"2014","unstructured":"Z\u00f6ller\u00a0B, Melander\u00a0O, Svensson\u00a0P, Engstr\u00f6m\u00a0G. Red cell distribution width and risk for venous thromboembolism: a\u00a0population-based cohort study. Thromb Res. 2014;133(3):334\u20139.","journal-title":"Thromb Res"},{"issue":"3","key":"1967_CR25","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.thromres.2015.07.020","volume":"136","author":"P Bucciarelli","year":"2015","unstructured":"Bucciarelli\u00a0P, Maino\u00a0A, Felicetta\u00a0I, Abbattista\u00a0M, Passamonti\u00a0SM, Artoni\u00a0A, et\u00a0al. Association between red cell distribution width and risk of venous thromboembolism. Thromb Res. 2015;136(3):590\u20134.","journal-title":"Thromb Res"},{"issue":"10","key":"1967_CR26","first-page":"E402","volume":"7","author":"E Danese","year":"2015","unstructured":"Danese\u00a0E, Lippi\u00a0G, Montagnana\u00a0M. Red blood cell distribution width and cardiovascular diseases. J\u00a0Thorac Dis. 2015;7(10):E402\u2013E11.","journal-title":"J Thorac Dis"},{"key":"1967_CR27","doi-asserted-by":"publisher","first-page":"102368","DOI":"10.1016\/j.bcmd.2019.102368","volume":"80","author":"I Kre\u010dak","year":"2020","unstructured":"Kre\u010dak\u00a0I, Kre\u010dak\u00a0F, Gveri\u0107-Kre\u010dak\u00a0V. High red blood cell distribution width might predict thrombosis in essential thrombocythemia and polycythemia vera. Blood Cells Mol Dis. 2020;80:102368.","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"1967_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000445247","volume":"136","author":"M Lucijanic","year":"2016","unstructured":"Lucijanic\u00a0M, Pejsa\u00a0V, Jaksic\u00a0O, Mitrovic\u00a0Z, Tomasovic-Loncaric\u00a0C, Stoos-Veic\u00a0T, et al. The degree of anisocytosis predicts survival in patients with primary myelofibrosis. Acta Haematol. 2016;136(2):98\u2013100.","journal-title":"Acta Haematol"},{"issue":"Supplement_1","key":"1967_CR29","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1182\/blood-2019-126410","volume":"134","author":"S Verstovsek","year":"2019","unstructured":"Verstovsek\u00a0S, De Stefano\u00a0V, Heidel\u00a0FH, Zuurman\u00a0M, Zaiac\u00a0M, Bigan\u00a0E, et al. US Optum database study in polycythemia vera patients: thromboembolic events (TEs) with hydroxyurea (HU) vs ruxolitinib switch therapy and machine-learning model to predict incidence of TEs and HU failure. Blood. 2019;134(Supplement_1):1659.","journal-title":"Blood"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-021-01967-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-021-01967-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-021-01967-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T14:28:30Z","timestamp":1645194510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-021-01967-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":29,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1967"],"URL":"https:\/\/doi.org\/10.1007\/s00508-021-01967-z","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"assertion":[{"value":"7 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I.\u00a0Kre\u010dak, M.\u00a0Lucijani\u0107, I.\u00a0Zekanovi\u0107, H.\u00a0Holik, M.\u00a0Mori\u0107 Peri\u0107, M.\u00a0\u0160upe, B.\u00a0Coha and V.\u00a0Gveri\u0107-Kre\u010dak declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}